The Transthyretin Amyloidosis Outcomes Survey (THAOS), established in 2007, is a longitudinal, observational study open to all physicians treating, and all individuals diagnosed with, or carrying a mutation that puts them at risk of transthyretin (TTR) amyloidosis. The data collected by THAOS will be used to inform and educate clinicians about the disease and its management.
The THAOS.net website provides information for patients, their caregivers and physicians about TTR amyloidosis.
New chair elected at scientific board meeting.
Dates for next investigator meeting announced.
New data released by the THAOS registry show over almost 2700 subjects are now enrolled. View the latest data from the registry here